Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Santhera Pharmaceuticals

Request full access

Santhera Pharmaceuticals is a Swiss specialty company dedicated to developing innovative medicines for rare neuromuscular diseases with significant unmet medical needs

Pratteln, SwitzerlandFounded 2004Biotech & Life Sciences

About Santhera Pharmaceuticals

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of therapies for rare neuromuscular and pulmonary diseases with high unmet medical needs. Founded in 2004 through the merger of two companies, MyoContract AG and Graffinity Pharmaceuticals AG, by Klaus Schollmeier, Thomas Meier, Stephan Witthauer, and Thomas von Romano, Santhera is headquartered in Pratteln, Switzerland.

The company's lead product is AGAMREE® (vamorolone), a dissociative steroid that has been approved in the European Union and the United Kingdom for the treatment of Duchenne muscular dystrophy (DMD). AGAMREE® works by binding to the same receptors as corticosteroids but modifies their downstream activity, demonstrating a similar efficacy profile to traditional corticosteroids with a favorable safety and tolerability profile. The U.S. Food and Drug Administration (FDA) also granted full approval for AGAMREE® for the treatment of DMD in patients aged two years and older. Santhera has out-licensed the rights for this drug in North America to Catalyst Pharmaceuticals and in China to Sperogenix Therapeutics.

Santhera's business model revolves around acquiring, developing, and commercializing treatments for orphan diseases. The company generates revenue through product sales and licensing agreements. It serves patients suffering from rare diseases where few or no treatment options exist, operating in the orphan drug market. The company has faced financial challenges, including a restructuring in 2019 after a clinical trial failure, but has since regained footing with the approval and launch of AGAMREE®.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2006
Outcome tier
Colt$25–100M revenue

Santhera Pharmaceuticals in the Pratteln ecosystem

Live from Dealroom

The Santhera Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • NGN Capital
  • Novartis Venture Fund

Series B and later2 investors entered at this stage

  • Highbridge Capital Management
  • CBC Group
Team profiled 28 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
11 countries with
team presence
🇨🇭 Switzerland63.3%
🇬🇧 United Kingdom7.8%
🇩🇪 Germany7.8%
🇳🇱 Netherlands4.4%
🇺🇸 United States4.4%
Top 5 of 11 shown
Web traffic by country
12K monthly visits
across markets
🇬🇧 United Kingdom65.8%
🇺🇸 United States14.2%
🇨🇭 Switzerland12.5%
🇮🇳 India7.5%
Top 4 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Santhera Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Santhera Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.